Pozen and Nycomed Enter into Option Agreement for NSAID Lornoxicam
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 39 (Table of Contents)
Published: 1 Aug-2003
DOI: 10.3833/pdr.v2003.i39.869 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pozen entered into an option agreement with Nycomed to acquire rights for Nycomed’s non-steroidal anti-inflammatory drug (NSAID), Lornoxicam for treating pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS